iScience
January 16, 2026
Amir Valizadeh, John D Roache, Xinyu Zhang et al.
2 citations
Post-traumatic stress disorder varies greatly in its clinical and biological features, making treatment difficult. The largest randomized trial of ketamine for PTSD found no overall benefit over placebo, highlighting the need to identify which patients might respond. Using pre-treatment blood DNA methylation profiles and clinical data from that trial, machine learning models predicted treatment response. A model based on 1,208 methylation sites outperformed models using only clinical variables, and combining both data types improved accuracy further. The methylation-derived score identified responders with 92.9% accuracy. Predictive methylation sites were near genes involved in glutamatergic signaling, immune regulation, and known PTSD risk loci, suggesting peripheral DNA methylation patterns can guide precision pharmacotherapy for PTSD.
Psychological Medicine
January 1, 2026
Ricarda Evens, Abdo Uyar, Emily Gosslau et al.
About 31% of people who had a distressing psychedelic experience that lasted beyond the acute phase met diagnostic criteria for post-traumatic stress disorder (PTSD). Avoidance during the acute experience predicted worse PTSD symptoms, while acceptance predicted milder symptoms. Post-traumatic growth was unrelated to the intensity of the challenge or avoidance but was linked to acceptance. Most participants sought help from online resources or friends, though psychotherapy was rated most helpful. The study targeted those with highly challenging experiences, so findings do not reflect prevalence among all psychedelic users.
Frontiers in psychiatry
January 1, 2026
Ngo Cheung
Four patients with hard-to-treat trauma-spectrum disorders—somatic PTSD, acute bereavement-related PTSD, trauma-linked adolescent depression, and complex PTSD with bipolar II, ADHD, and borderline features—showed clinically meaningful symptom improvement within days to weeks after starting an inexpensive oral protocol centered on dextromethorphan potentiated by fluoxetine, with optional piracetam or bupropion. Reductions in intrusive memories, rumination, somatic pain, and functional disability were noted; no episodes of dissociation, hypertension, or mania were clinically documented during follow-up, though structured screening for hypomania and serotonergic toxicity was not performed. The findings are hypothesis-generating and suggest further controlled investigation of oral NMDA-AMPA modulators for trauma-related conditions.
Journal of neuroendocrinology
January 1, 2026
Hiroe Hu, Yoojin Lee, Alaina N Tillman et al.
1 citation
People with both major depression and post-traumatic stress disorder (PTSD) have lower baseline levels of copeptin, a stable marker of vasopressin secretion, and a blunted reduction in copeptin after a single low-dose ketamine infusion compared to those with depression alone. Copeptin levels were unrelated to depression diagnosis or symptom severity of depression, anxiety, PTSD, anhedonia, suicidal ideation, or childhood trauma, but higher copeptin was linked to verbal aggression, an association weakened by PTSD. These findings point to a possible biological subtype of reduced vasopressin activity in co-occurring depression and PTSD, suggesting copeptin may serve as a peripheral biomarker for central vasopressin-driven circuits in neuropsychiatric disorders.
Case Reports in Psychiatry
January 1, 2026
Ridhi J. Vyas, Ryan Hood, Jeremy Hsiang et al.
A 31-year-old woman with chronic PTSD and a history of childhood compulsions developed new-onset obsessive-compulsive disorder (OCD) after undergoing MDMA-assisted psychotherapy (MDMA-AP) in a clinical trial. Her PTSD had been resistant to multiple medications, and she reported significant improvements in flashbacks and suicidal ideation after the first session. Following a delayed second session, she experienced intrusive guilt, scrupulosity, and compulsive urges to confess, leading to a DSM-5 diagnosis of OCD. OCD symptoms persisted for over a year, with a Y-BOCS score of 17 indicating moderate severity, and improved with escitalopram. This case suggests that MDMA-AP may trigger obsessive-compulsive pathology in individuals with complex trauma and prior obsessive-compulsive tendencies, possibly through serotonergic effects on frontostriatal circuits, and highlights the need for screening and long-term monitoring in such protocols.